Nasdaq· CIK 0001549084

CHRN

ChronoScale Holdings Corp
$19.21 ▼ -0.83%
Prev close $19.37
Market cap$2.9B
ConsensusBuy
12-mo target$32.00 (+66.6%)
▲ Bullish
Analyst conviction 8/10
Snapshot
The big-picture read on CHRN right now — valuation, ownership and activity at a glance.
Market Cap
$2.9B
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (75%)
Inst. Holders
32 funds
Inst. Value
$23.4M
Social Sentiment
33° Cool
SEC Reports
6
Price chart 30d -4.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 contract
ChronoScale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue to $1 Billion and Sale of Ekso Bionics Business Unit
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- ChronoScale Holdings Corporation (NASDAQ: CHRN
Aug 18, 2026 SEC
ChronoScale Holdings Corp entered into a formal offer letter with CFO Jerome Wong on August 16, 2026, formalizing his co
8-K — Impact 2/10
Aug 16, 2026 Insider
Wong Jerome was granted 300,000 shares
Chief Financial Officer
Jul 22, 2026 Insider
Jegannathan Rajasekar was granted 1,400,000 shares
Chief Technology Officer
Jul 16, 2026 SEC
ChronoScale's S-3 registration statement (File No. 333-297176) became effective on July 15, 2026, enabling the resale of
EFFECT — Impact 3/10
Jul 13, 2026 Insider
Chen Ying Cenly was granted 2,800,000 shares
Chief Executive Officer
Jul 3, 2026 SEC
ChronoScale Corp entered into a $100M unsecured demand promissory note with Applied Digital Corporation, its 96% majorit
8-K — Impact 4/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Buy 75% rate it Buy or better · 8 analysts
Strong Buy 2 25% Buy 4 50% Hold 2 25% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 18, 2026Northland Capital MarketsINITIATEOutperform 51%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 20262420075%
Aug 1, 20262420075%
Jul 1, 20262420075%
Jun 1, 20262420075%
May 1, 20262420075%
Apr 1, 20262420075%
Mar 1, 20262420075%
Feb 1, 20262420075%
Price targets
Where 1 covering analysts think CHRN trades over the next 12 months.
$32.00 +66.6% upside Strong Buy
Current$19.21 Low$32.00 Median$32.00 High$32.00 1 analysts
$32.00$32.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
2 mentions 0 bullish 2 bearish 0 neutral
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 3.7/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
contract
ChronoScale Announces Agreements Bringing Total Company Contracted Run-Rate Revenue to $1 Billion and Sale of Ekso Bionics Business Unit
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated
Sep 10, 2026
ftd
FTD: CHRN — 37,731 shares ($0.7M) failed to deliver
Settlement: 20260910, Price: $18.18, FTD Value: $685,949.58, CHRONOSCALE HOLDINGS CORPORATI
Jul 27, 2026
earnings_calendar
CHRN Q2 2026 Earnings Scheduled — 2026-07-27
Jul 24, 2026
ftd
FTD: CHRN — 34,741 shares ($0.8M) failed to deliver
Settlement: 20260724, Price: $22.57, FTD Value: $784,104.37, CHRONOSCALE HOLDINGS CORPORATI
Jul 16, 2026
ftd
FTD: CHRN — 35,070 shares ($1.0M) failed to deliver
Settlement: 20260716, Price: $29.63, FTD Value: $1,039,124.1, CHRONOSCALE HOLDINGS CORPORATI
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.09$-0.09–$-0.09———$0.0B1
Next Q$-0.08$-0.08–$-0.08———$0.0B1
Current FY$-0.81$-0.81–$-0.81———$0.2B1
Next FY$-1.73$-1.73–$-1.73-113.6%——$1.5B1
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.090—
7d ago$0.000-0.090
30d ago$0.000-0.090
60d ago$0.000-0.090
90d ago$0.000-0.090
Institutional ownership
Which big funds own CHRN (from quarterly 13F filings) and who is adding or trimming.
32 institutional holders with $23.4M total value (1,052,211 shares) as of 2026-Q2. Top holders: Vident, Hood, MILLENNIUM.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
Vident Advisory, LLC333,705$7.4M31.7%—
Hood River Capital Management LLC118,011$2.6M11.2%—
MILLENNIUM MANAGEMENT LLC72,275$1.6M6.9%—
Vontobel Holding Ltd.61,652$1.4M5.9%—
Point72 Asset Management, L.P.59,793$1.3M5.7%—
GEODE CAPITAL MANAGEMENT, LLC57,119$1.3M5.4%—
BANK OF AMERICA CORP /DE/39,325$873.8K3.7%—
MORGAN STANLEY37,831$840.6K3.6%—
VANGUARD CAPITAL MANAGEMENT LLC37,583$835.1K3.6%—
Brevan Howard Capital Management LP31,725$704.9K3.0%—
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
Aug 16, 2026Wong JeromeChief Financial OfficerAWARD300,000——
Jul 22, 2026Jegannathan RajasekarChief Technology OfficerAWARD1,400,000——
Jul 13, 2026Chen Ying CenlyChief Executive OfficerAWARD2,800,000——
Jun 29, 2026Schaap Andrew CordellDirectorAWARD200,000——
May 14, 2026CLANCY WILLIAM MDirectorAWARD200,000——
May 14, 2026Wong JeromeChief Financial OfficerAWARD40,000——
May 14, 2026Cummins WesDirectorAWARD200,000——
May 14, 2026Benson Ella G.DirectorAWARD200,000——
May 14, 2026Nottenburg Richard NDirectorAWARD200,000——
May 14, 2026MILLER DOUGLAS SDirectorAWARD200,000——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CHRN.
Shares short
701,226
Settlement Sep 15, 2026
Change vs prior
+9.8%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈0.5%
Estimate — not % of float
All CHRN filing & press-release reports (6)